Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (3075)	9/14/2005 8:59:19 PM
From: Ian@SI	Read Replies (1) \| Respond to of 12215

Here's what Briefing had to say on CELG. Sounds like a bit of a disservice to its readers given the vote on Q2. 01:49 ET Celgene confirms FDA Oncologic Drugs Advisory Committee recommends Revlimid for full approval (CELG) 52.91 +0.00: -Update- Co confirmed that the Oncologic Drugs Advisory Committee of the FDA recommended full approval of Revlimid for the treatment of patients with transfusion- dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. (Stock is halted)